The first XFem Labs research project, supported by the Gates Foundation, aims to accelerate the development of non-hormonal contraceptives, in particular for women in low- and middle-income countries via BioMed X’s global talent sourcing and incubation model.
HEIDELBERG, Germany, October 14, 2025 / Biotech Newswire / -- BioMed X today announced the launch of XFem Labs, a new Women’s Health R&D Accelerator in Heidelberg. The purpose of this initiative, which is supported by the Gates Foundation, is to establish a world-class women’s health innovation hub that advances early-stage research into scalable solutions for women in need around the world, including low- and middle-income countries.
Embedded within the academic environments of the University of Heidelberg and Yale, and directly within R&D campuses of leading pharmaceutical companies, BioMed X bridges the translational gap between academia and industry to drive transformative innovation.
The first project at the new XFem Labs accelerator in Heidelberg is entitled “New Strategies for Female-Controlled Non-Hormonal Contraception”. Despite the availability of various contraceptive methods, 257 million women worldwide still face significant barriers to access. Current hormonal contraceptives are often associated with side effects, such as changes in bleeding patterns, resulting in high discontinuation rates. Non-hormonal, female-controlled alternatives remain limited and often challenging, hence there is an urgent need for new options.
The first XFem Labs call for application invites proposals that explore new biological targets, molecular mechanisms, or delivery modalities for continuous and/or on-demand non-hormonal contraception. Selected researchers will participate in a boot camp at BioMed X, resulting in the incubation of a new research team based In Heidelberg.
“Our joint goal with the Gates Foundation is to create a significant impact on the lives and health of women world-wide,” said Dr. Christian Tidona, CEO of BioMed X. “Together with an international network of top experts and key opinion leaders, we will jointly build and mentor new outstanding research teams who will strive to solve some of the most pressing challenges in women’s health.”
Researchers interested in becoming part of this new research group are invited to respond to this international call by submitting a project proposal via the BioMed X Career Space at https://career.bmedx.com/call/2025-XFL-C01 before December 7, 2025.
This first XFem Labs project is made possible with a $2 million grant and network support from the Gates Foundation.
For high resolution please click the image.
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. We operate at the interface between academia and industry, performing biomedical research and drug discovery & development in the fields of oncology, immunology, neuroscience, women’s health, cardiometabolic diseases, platform technologies, and artificial intelligence.
All our research projects are supported by leading pharmaceutical companies or other external funding sources and conducted by early-career scientists recruited from the best schools around the world. The combination of global crowdsourcing with local incubation of the best research talents and ideas allows us to solve the biggest challenges in biomedical research.
We stand for free, creative, and curiosity-driven research combined with a solid validation of results, timelines, and deliverables. We serve a large purpose in advancing translational biomedicine by leveraging synergies and fostering cross-pollination across disciplines.
Link to the German version.
Contact
BioMed X
Maria Morganti
VP Head of Marketing & Communications
+49 6221 42611 30
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: International Cooperation; Biomedical Research; Contraceptive Agents, Female; Contraceptives, Oral, Hormonal; BioMed X; XFem Labs; Women’s Health R&D Accelerator; Heidelberg; Gates Foundation; non-hormonal contraceptives; female-controlled contraception; on-demand contraception; boot camp; research incubation; Dr. Christian Tidona; international network; women’s health innovation; BioMed X Career Space; $2 million grant
Source: Biotech Newswire